
An experimental vaccine against the coronavirus showed encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers, its maker announced Monday. Study volunteers given either a low or medium dose of the vaccine by Cambridge, Massachusetts-based Moderna Inc. had antibodies similar to those seen in people who have recovered from COVID-19. TO OUR READERS: This content is being provided…
More Stories
Brazil rolls out COVID-19 vaccination plan
First Pfizer COVID-19 vaccine shipments to be delivered to US distribution sites starting Monday
CDC advisory panel recommends Covid-19 vaccine for people 16 and over